Oak Family Advisors LLC Sells 37,733 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Oak Family Advisors sold 37,733 shares, trimming its Zimmer Biomet stake by 44.7% and leaving 46,590 shares worth about $4.19 million at the end of the quarter.
• Zimmer Biomet beat quarterly estimates, reporting $2.09 EPS vs. $1.86 expected and $2.09 billion in revenue (up 9.3% year‑over‑year), and set FY2026 guidance of $8.400–$8.550 EPS.
• The stock carries an average analyst rating of "Hold" with an average target price of $102.80.

Oak Family Advisors LLC trimmed its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 44.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 46,590 shares of the medical equipment provider's stock after selling 37,733 shares during the quarter. Oak Family Advisors LLC's holdings in Zimmer Biomet were worth $4,189,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the company. WealthShield Partners LLC increased its stake in Zimmer Biomet by 6.7% in the fourth quarter. WealthShield Partners LLC now owns 2,517 shares of the medical equipment provider's stock valued at $226,000 after acquiring an additional 158 shares during the last quarter. K.J. Harrison & Partners Inc bought a new position in Zimmer Biomet in the fourth quarter valued at approximately $452,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in Zimmer Biomet by 3.0% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 411,736 shares of the medical equipment provider's stock valued at $37,064,000 after acquiring an additional 11,910 shares during the last quarter. PKO Investment Management Joint Stock Co increased its stake in Zimmer Biomet by 48.0% in the fourth quarter. PKO Investment Management Joint Stock Co now owns 3,700 shares of the medical equipment provider's stock valued at $333,000 after acquiring an additional 1,200 shares during the last quarter. Finally, Strs Ohio increased its stake in Zimmer Biomet by 3.7% in the fourth quarter. Strs Ohio now owns 222,744 shares of the medical equipment provider's stock valued at $20,029,000 after acquiring an additional 8,009 shares during the last quarter. 88.89% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ZBH. Wells Fargo & Company decreased their price objective on shares of Zimmer Biomet from $98.00 to $90.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 29th. Leerink Partners began coverage on shares of Zimmer Biomet in a research note on Monday, April 13th. They issued a "hold" rating and a $101.00 price objective on the stock. Wall Street Zen cut shares of Zimmer Biomet from a "buy" rating to a "hold" rating in a research note on Sunday, April 19th. Canaccord Genuity Group set a $83.00 target price on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Finally, TD Cowen upgraded shares of Zimmer Biomet from a "hold" rating to a "buy" rating in a research report on Monday, January 26th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, Zimmer Biomet currently has an average rating of "Hold" and an average target price of $102.80.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock opened at $83.38 on Friday. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $79.83 and a fifty-two week high of $108.29. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95. The firm has a market capitalization of $16.13 billion, a P/E ratio of 21.66, a P/E/G ratio of 1.91 and a beta of 0.48. The company's 50 day moving average price is $91.56 and its two-hundred day moving average price is $92.31.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, beating analysts' consensus estimates of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The firm had revenue of $2.09 billion for the quarter, compared to analyst estimates of $2.07 billion. During the same quarter last year, the business posted $1.81 earnings per share. The company's quarterly revenue was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.47 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st were given a $0.24 dividend. The ex-dividend date was Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 1.2%. Zimmer Biomet's dividend payout ratio (DPR) is currently 24.94%.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 2,650 shares of Zimmer Biomet stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the transaction, the senior vice president owned 10,224 shares in the company, valued at approximately $967,803.84. The trade was a 20.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.28% of the company's stock.

About Zimmer Biomet

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.